Literature DB >> 11592601

Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1.

J D Jia1, M Bauer, J J Cho, M Ruehl, S Milani, G Boigk, E O Riecken, D Schuppan.   

Abstract

BACKGROUND/AIMS: Silymarin reduces hepatic collagen accumulation by 35% in rats with secondary biliary cirrhosis. The aim of the present study was to explore its antifibrotic mechanism.
METHODS: Thirty female adult Wistar rats were allocated to (1) bile duct occlusion, (2) bile duct occlusion and oral silymarin at 50 mg/kg per day, and (3) sham operation and oral silymarin at 50 mg/kg per day. Steady-state mRNA levels for procollagen alpha1(I), tissue inhibitor of metalloproteinases-1 (TIMP-1), and transforming growth factor (TGF) beta1 were determined by multi-probe ribonuclease protection assay.
RESULTS: After 6 weeks of bile duct occlusion, liver collagen content was increased 12-fold, when compared with the sham-operated controls. These animals displayed 17-, 6.5- and 16-fold higher transcript levels for procollagen alpha1(I), TIMP-1 and TGFbeta1 (P < 0.01). Silymarin downregulated elevated procollagen alpha1(I), TIMP-1 and TGFbeta1 mRNA levels by 40-60% (P < 0.01). These lowered hepatic profibrogenic transcript levels correlated with decreased serum levels of the aminoterminal propeptide of procollagen type III.
CONCLUSIONS: Silymarin suppresses expression of profibrogenic procollagen alpha1(I) and TIMP-1 most likely via downregulation of TGFbeta1 mRNA in rats with biliary fibrosis. The serum procollagen type III propeptide level mirrors profibrogenic mRNA expression in the liver.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592601     DOI: 10.1016/s0168-8278(01)00148-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

1.  Effects of long-term silymarin oral supplementation on the blood biochemical profile of rainbow trout (Oncorhynchus mykiss).

Authors:  Mahdi Banaee; Antoni Sureda; Ali Reza Mirvaghefi; Golam Reza Rafei
Journal:  Fish Physiol Biochem       Date:  2011-04-26       Impact factor: 2.794

Review 2.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

Review 3.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 4.  Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-13       Impact factor: 3.199

5.  Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat.

Authors:  Hossein Najafzadeh; Mohammad Razi Jalali; Hassan Morovvati; Farnaz Taravati
Journal:  J Med Toxicol       Date:  2010-03

6.  Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis.

Authors:  Da-Hee Jeong; Gi-Ppeum Lee; Won-Il Jeong; Sun-Hee Do; Hai-Jie Yang; Dong-Wei Yuan; Ho-Yong Park; Kyu-Jong Kim; Kyu-Shik Jeong
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

7.  Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis.

Authors:  Gopalakrishnan Ramakrishnan; Sundaram Jagan; Sattu Kamaraj; Pandi Anandakumar; Thiruvengadam Devaki
Journal:  Invest New Drugs       Date:  2008-07-30       Impact factor: 3.850

8.  Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Authors:  Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

9.  Down-regulation of transforming growth factor beta 1/activin receptor-like kinase 1 pathway gene expression by herbal compound 861 is related to deactivation of LX-2 cells.

Authors:  Li Li; Xin-Yan Zhao; Bao-En Wang
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

10.  Inhibitory effects of armepavine against hepatic fibrosis in rats.

Authors:  Ting-Chun Weng; Chien-Chang Shen; Yung-Tsung Chiu; Yun-Lian Lin; Cheng-Deng Kuo; Yi-Tsau Huang
Journal:  J Biomed Sci       Date:  2009-09-02       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.